The canine atopic dermatitis treatment market size expects a considerable valuation bump, from US$ 1,182.60 million in 2024 to US$ 1,620.50 million in 2034. The updated report points to a CAGR of 3.20% CAGR from 2024 to 2034. That is a significant dip from the previous CAGR of 7.60% observed between 2019 and 2023.
| Attributes | Details |
|---|---|
| Canine Atopic Dermatitis Treatment Market Size, 2023 | US$ 1,192.20 million |
| Canine Atopic Dermatitis Treatment Market Size, 2024 | US$ 1,182.60 million |
| Canine Atopic Dermatitis Treatment Market Size, 2034 | US$ 1,620.50 million |
| Value CAGR (2024 to 2034) | 3.20% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Fundings for Developing Regenerative Medicines Rise in the Market
New treatments are being developed to help canines with itchy skin. These treatments comprise stem cell therapy and Platelet-rich Plasma (PRP) injections. Some other effective products for treating CAD are Cytopoint (lokivetmab), cASCs or cASC-EVs, and Oclacitinib Maleate (Apoquel, Zoetis). These dog allergy treatments use the body’s natural healing powers to repair the skin.
They also reduce swelling and make the immune system stronger. They calm down the immune system and use special cells to fix skin damage. These treatments can help canines in the long run. As such, more research is being conducted on the potential of regenerative medicines. Investments are flooding in the veterinary dermatology market to develop these treatment approaches more effectively.
For example, Gallant Therapeutics raised over US$ 15 million in Series A Funding in January 2024. The top investors were BOLD Capital, Digitalis Ventures, and Hill Creek Partners. The funding has accelerated the company’s pipeline development of allogeneic stem cell therapeutics.
Global Rise in Pet Ownership Fosters Market Growth
More people around the world are getting pets. This is especially true in places where the economy is growing. This means that there are more canines needing treatment for skin problems like canine atopic dermatitis.
In countries where more people are becoming wealthier, there’s a higher need for vets and treatment for pets. Pet humanization trends also contribute to this. Rise in middle-class populations and shifting societal attitudes toward pets aid market growth.
It is estimated that 33% of households have a pet. There are nearly 471 million pet dogs and 370 million pet cats globally. Dogs make up for the top category of insured pets.
Principal Consultant
| Segment | Immunosuppressants (Drug Class) |
|---|---|
| Value Share (2024) | 42.10% |
The immunosuppressants segment garnered top canine atopic dermatitis treatment market shares in 2024. The cases and severity of atopic dermatitis in canines are rising. As such, effective treatment solutions like immunosuppressants are being demanded. Immunosuppressants like calcineurin inhibitors and corticosteroids can effectually control the symptoms of this disease.
There are cases where secondary bacterial infections happen. In these types of cases, immunosuppressants are used as an aide for antibiotic therapy. The market shares of this segment are high because they can be used in comprehensive treatment plans for the long-term management of CAD.
| Segment | Oral (Route of Administration) |
|---|---|
| Value Share (2024) | 46.70% |
The oral route of administration segment holds the top canine atopic dermatitis treatment market shares in 2024. Oral medications are popular for cAD treatment. They’re easy to administer and work throughout the whole body. They are especially useful for giving relief beyond just the surface. Vets can adjust doses on how bad the symptoms are and how the canine responds.
Oral meds last longer than creams. This makes it easier for pet owners to manage the disease. They also reduce the need for strong steroids that can have side effects. New oral cAD treatment medications are hitting the market. They come with better tastes and are easier to swallow. This makes it preferrable in the market among pet owners and vets.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| United States | 1.90% |
| Germany | 2.70% |
| Malaysia | 3.90% |
| Thailand | 4.20% |
| India | 5.30% |
The demand for canine atopic dermatitis treatment in the United States to rise at a 1.90% CAGR till 2034. More pet owners are getting insurance for their pet animals. During the end of 2022, it was noticed that nearly 4.8 million pets were insured in the United States. Pet owners tend to pay more for specialized care as they get concerned about the health of their animals. So, companies can make specialized or personalized medicines for canine skin allergies.
There are also the FDA’s Center for Veterinary Medicine (CVM) Innovation Initiatives and the Minor Use and Minor Species (MUMS) designation. The presence of these programs makes it easier to get drug approvals and bring them to the market.
Zoetis Inc. and Elanco Animal Health are valuable in the United States. They are among the top players in the United States market. These companies invest in R&D heavily to launch new dermatology products for canines.
The sales of canine atopic dermatitis treatment in Germany will increase at a 2.70% CAGR until 2034. Allergies, like atopic dermatitis, are common here due to pollen and dust, so there's a big need for dog skin allergy treatments. This is leading to more research and new medicines.
In Germany, people adore their pets and spend a lots on their health, especially for skin issues like atopic dermatitis in canines. Germany has many vet clinics and experts in pet skin problems, which helps in finding better treatments. Some German pet owners are also showing a preference for natural remedies, like herbs or homeopathy. This is creating a small market niche for these treatments.
Bayer AG and Virbac GmbH are prominent in Germany. They are famous for their product innovations and consumer-centric approaches. They provide comprehensive support to vets and pet owners.
The canine atopic dermatitis treatment market growth in Malaysia is estimated at a 3.90% CAGR through 2034. Atopic dermatitis in canines is common due to Malaysia’s warm and humid climate. Nearly 51.1% of the country’s population has a pet. Cats are more adopted than cats here.
Nearly 77.7% of pet owners have at least one cat and 14.9% of pet owners have dogs. The pet humanization trend is picking up heat here. Also, the middle-class population is growing in Malaysia. These factors are letting people invest in veterinary dermatology and aiding market development.
Biovet Sdn Bhd and Merial Malaysia Sdn Bhd are eminent in Malaysia. These businesses focus on marketing efforts to reach a wider audience. They also ally with local partners to widen their networks.
Canine atopic dermatitis treatment demand in Thailand shall amplify at a 4.20% CAGR till 2034. The pet healthcare industry in Thailand is maturing. Urbanization in the country is leading to a spike in pet ownership. Thai people treat their pets like family and want good healthcare for them. Pet humanization trends are going to intensify and aid in market growth in Thailand.
Merck Animal Health and Ceva Animal Health (Thailand) Co. Ltd. are headquartered here. These businesses focus on alliances with local distributors. They also provide training and support to vets.
Canine atopic dermatitis treatment sales in India can increase at a 5.30% CAGR till 2034. People from countries like Bangladesh, Nepal, and Sri Lanka visit India for cheaper vet care.
Affordable care is important in India due to the price-sensitive populace. India’s pet population is also growing. Dog lovers account for nearly 68% of the population, while cats belong to nearly 20% of Indian pet owners. As more people are getting pets, the demand for canine atopic dermatitis treatment is bound to increase in India.
Indian Immunologists Limited (IIL) and Intas Pharmaceuticals Ltd. are located here. These businesses are increasing their offering portfolios to launch innovative solutions. They also want them to be cost-effective, so research is an all-time necessity for these businesses.
The canine atopic dermatitis treatment market is highly competitive. The arena is ruled by leading companies including Zoetis Inc., Elanco Animal Health, and Bayer Animal Health. To sustain their supremacy, these corporations rely on broad product portfolios and reach.
Other important rivals include Virbac, Ceva Animal Health, and Vetoquinol. Also, businesses like Dechra Pharmaceuticals, Boehringer Ingelheim Animal Health, and Merial (now a part of Boehringer Ingelheim) are improving their presence in the market through collaborations and acquisitions. Regulatory compliance, pricing diplomacies, and technical improvements make up for the competitiveness of this market.
Recent Developments
The canine atopic dermatitis treatment industry is valued at US$ 1,82.60 million in 2024.
The market is estimated to increase at a 3.20% CAGR through 2034.
The market is expected to be worth US$ 1,620.50 million by 2034.
Immunosuppressants are highly preferred in the market.
The market in India is predicted to expand at a 5.30% CAGR through 2034.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Manufacturer 3.5.1.2. Mid-Level Participants (Traders) 3.5.1.3. Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Distributors 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 4.1. Historical Market Size Value (US$ Billion) & Volume (Units) Analysis, 2019 to 2023 4.2. Current and Future Market Size Value (US$ Billion) & Volume (Units) Projections, 2024 to 2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Billion) & Volume (Units) Analysis By Drug Class, 2019 to 2023 5.3. Current and Future Market Size Value (US$ Billion) & Volume (Units) Analysis and Forecast By Drug Class, 2024 to 2034 5.3.1. Corticosteroids 5.3.2. Immunosuppressant 5.3.3. Antibiotics 5.3.4. Antihistamines 5.3.5. Emollients 5.3.6. Essential Fatty Acids 5.3.7. Antipruritic 5.3.8. Monoclonal Antibodies 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2019 to 2023 5.5. Absolute $ Opportunity Analysis By Drug Class, 2024 to 2034 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Billion) & Volume (Units) Analysis By Route of Administration, 2019 to 2023 6.3. Current and Future Market Size Value (US$ Billion) & Volume (Units) Analysis and Forecast By Route of Administration, 2024 to 2034 6.3.1. Topical 6.3.2. Oral 6.3.3. Injectable 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2019 to 2023 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Billion) & Volume (Units) Analysis By Distribution Channel, 2019 to 2023 7.3. Current and Future Market Size Value (US$ Billion) & Volume (Units) Analysis and Forecast By Distribution Channel, 2024 to 2034 7.3.1. Veterinary Hospitals 7.3.2. Veterinary Clinics 7.3.3. Retail Pharmacies 7.3.4. Drug Stores 7.3.5. Mail Order Pharmacies 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Billion) & Volume (Units) Analysis By Region, 2019 to 2023 8.3. Current Market Size Value (US$ Billion) & Volume (Units) Analysis and Forecast By Region, 2024 to 2034 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. South Asia and Pacific 8.3.6. East Asia 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 9.1. Historical Market Size Value (US$ Billion) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 9.2. Market Size Value (US$ Billion) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Drug Class 9.2.3. By Route of Administration 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Class 9.3.3. By Route of Administration 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10.1. Historical Market Size Value (US$ Billion) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 10.2. Market Size Value (US$ Billion) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Class 10.2.3. By Route of Administration 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Route of Administration 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11.1. Historical Market Size Value (US$ Billion) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 11.2. Market Size Value (US$ Billion) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. UK 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Western Europe 11.2.2. By Drug Class 11.2.3. By Route of Administration 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Route of Administration 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12.1. Historical Market Size Value (US$ Billion) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 12.2. Market Size Value (US$ Billion) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Czech Republic 12.2.1.4. Romania 12.2.1.5. Rest of Eastern Europe 12.2.2. By Drug Class 12.2.3. By Route of Administration 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Route of Administration 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13.1. Historical Market Size Value (US$ Billion) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 13.2. Market Size Value (US$ Billion) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Bangladesh 13.2.1.3. Australia 13.2.1.4. New Zealand 13.2.1.5. Rest of South Asia and Pacific 13.2.2. By Drug Class 13.2.3. By Route of Administration 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Route of Administration 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14.1. Historical Market Size Value (US$ Billion) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 14.2. Market Size Value (US$ Billion) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Drug Class 14.2.3. By Route of Administration 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Route of Administration 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 15.1. Historical Market Size Value (US$ Billion) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 15.2. Market Size Value (US$ Billion) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Drug Class 15.2.3. By Route of Administration 15.2.4. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Class 15.3.3. By Route of Administration 15.3.4. By Distribution Channel 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2023 16.1.2.1. By Drug Class 16.1.2.2. By Route of Administration 16.1.2.3. By Distribution Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2023 16.2.2.1. By Drug Class 16.2.2.2. By Route of Administration 16.2.2.3. By Distribution Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2023 16.3.2.1. By Drug Class 16.3.2.2. By Route of Administration 16.3.2.3. By Distribution Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2023 16.4.2.1. By Drug Class 16.4.2.2. By Route of Administration 16.4.2.3. By Distribution Channel 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2023 16.5.2.1. By Drug Class 16.5.2.2. By Route of Administration 16.5.2.3. By Distribution Channel 16.6. UK 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2023 16.6.2.1. By Drug Class 16.6.2.2. By Route of Administration 16.6.2.3. By Distribution Channel 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2023 16.7.2.1. By Drug Class 16.7.2.2. By Route of Administration 16.7.2.3. By Distribution Channel 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2023 16.8.2.1. By Drug Class 16.8.2.2. By Route of Administration 16.8.2.3. By Distribution Channel 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2023 16.9.2.1. By Drug Class 16.9.2.2. By Route of Administration 16.9.2.3. By Distribution Channel 16.10. Poland 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2023 16.10.2.1. By Drug Class 16.10.2.2. By Route of Administration 16.10.2.3. By Distribution Channel 16.11. Russia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2023 16.11.2.1. By Drug Class 16.11.2.2. By Route of Administration 16.11.2.3. By Distribution Channel 16.12. Czech Republic 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2023 16.12.2.1. By Drug Class 16.12.2.2. By Route of Administration 16.12.2.3. By Distribution Channel 16.13. Romania 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2023 16.13.2.1. By Drug Class 16.13.2.2. By Route of Administration 16.13.2.3. By Distribution Channel 16.14. India 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2023 16.14.2.1. By Drug Class 16.14.2.2. By Route of Administration 16.14.2.3. By Distribution Channel 16.15. Bangladesh 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2023 16.15.2.1. By Drug Class 16.15.2.2. By Route of Administration 16.15.2.3. By Distribution Channel 16.16. Australia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2023 16.16.2.1. By Drug Class 16.16.2.2. By Route of Administration 16.16.2.3. By Distribution Channel 16.17. New Zealand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2023 16.17.2.1. By Drug Class 16.17.2.2. By Route of Administration 16.17.2.3. By Distribution Channel 16.18. China 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2023 16.18.2.1. By Drug Class 16.18.2.2. By Route of Administration 16.18.2.3. By Distribution Channel 16.19. Japan 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2023 16.19.2.1. By Drug Class 16.19.2.2. By Route of Administration 16.19.2.3. By Distribution Channel 16.20. South Korea 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2023 16.20.2.1. By Drug Class 16.20.2.2. By Route of Administration 16.20.2.3. By Distribution Channel 16.21. GCC Countries 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2023 16.21.2.1. By Drug Class 16.21.2.2. By Route of Administration 16.21.2.3. By Distribution Channel 16.22. South Africa 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2023 16.22.2.1. By Drug Class 16.22.2.2. By Route of Administration 16.22.2.3. By Distribution Channel 16.23. Israel 16.23.1. Pricing Analysis 16.23.2. Market Share Analysis, 2023 16.23.2.1. By Drug Class 16.23.2.2. By Route of Administration 16.23.2.3. By Distribution Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Drug Class 17.3.3. By Route of Administration 17.3.4. By Distribution Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Zoetis Inc. 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.1.5.2. Product Strategy 18.1.1.5.3. Channel Strategy 18.1.2. Elanco Animal Health Incorporated 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.2.5.2. Product Strategy 18.1.2.5.3. Channel Strategy 18.1.3. Virbac 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.3.5.2. Product Strategy 18.1.3.5.3. Channel Strategy 18.1.4. Elanco Animal Health 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.4.5.2. Product Strategy 18.1.4.5.3. Channel Strategy 18.1.5. Merck KGaA 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.5.5.2. Product Strategy 18.1.5.5.3. Channel Strategy 18.1.6. Johnson & Johnson Services, Inc. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.6.5.2. Product Strategy 18.1.6.5.3. Channel Strategy 18.1.7. Kindred Biosciences, Inc. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.7.5.2. Product Strategy 18.1.7.5.3. Channel Strategy 18.1.8. Nippon Zenyaku Kogyo Co., Ltd. 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.8.5.2. Product Strategy 18.1.8.5.3. Channel Strategy 18.1.9. Bioiberica S.A.U 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.9.5.2. Product Strategy 18.1.9.5.3. Channel Strategy 18.1.10. Dechra Pharmaceuticals PLC 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.10.5.2. Product Strategy 18.1.10.5.3. Channel Strategy 18.1.11. Toray Industries, Inc. 18.1.11.1. Overview 18.1.11.2. Product Portfolio 18.1.11.3. Profitability by Market Segments 18.1.11.4. Sales Footprint 18.1.11.5. Strategy Overview 18.1.11.5.1. Marketing Strategy 18.1.11.5.2. Product Strategy 18.1.11.5.3. Channel Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Canine Atopic Dermatitis Treatment Market
